Literature DB >> 22511706

Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?

Joshua P Lewis, Alan R Shuldiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22511706      PMCID： PMC3715313          DOI： 10.1161/CIRCGENETICS.112.962910

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN： 1942-3268


× No keyword cloud information.
  17 in total

1.  Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.

Authors:  J P Lewis; A S Fisch; K Ryan; J R O'Connell; Q Gibson; B D Mitchell; H Shen; K Tanner; R B Horenstein; R Pakzy; U S Tantry; K P Bliden; P A Gurbel; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-08-31       Impact factor: 6.875

2.  Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.

Authors:  P Fontana; R James; I Barazer; P Berdagué; J-F Schved; M Rebsamen; N Vuilleumier; J-L Reny
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

3.  The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.

Authors:  S R Mehta; S Yusuf
Journal:  Eur Heart J       Date:  2000-12       Impact factor: 29.983

4.  Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.

Authors:  S Connolly; S Yusuf; A Budaj; J Camm; S Chrolavicius; P J Commerford; M Flather; K A A Fox; R Hart; S Hohnloser; C Joyner; M Pfeffer; I Anand; H Arthur; A Avezum; M Bethala-Sithya; M Blumenthal; L Ceremuzynski; R De Caterina; R Diaz; G Flaker; G Frangin; M-G Franzosi; C Gaudin; S Golitsyn; S Goldhaber; C Granger; D Halon; A Hermosillo; D Hunt; P Jansky; N Karatzas; M Keltai; F Lanas; C P Lau; J-Y Le Heuzey; B S Lewis; J Morais; C Morillo; A Oto; E Paolasso; R J Peters; M Pfisterer; L Piegas; T Pipillis; C Proste; E Sitkei; K Swedberg; D Synhorst; M Talajic; V Trégou; V Valentin; W van Mieghem; W Weintraub; J Varigos
Journal:  Am Heart J       Date:  2006-06       Impact factor: 4.749

5.  Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Authors:  Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

6.  Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

Authors:  Dietmar Trenk; Willibald Hochholzer; Martin F Fromm; Oliver Zolk; Christian M Valina; Christian Stratz; Franz-Josef Neumann
Journal:  Circ Cardiovasc Genet       Date:  2011-06-17

7.  No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Authors:  Dirk Sibbing; Werner Koch; Steffen Massberg; Robert A Byrne; Julinda Mehilli; Stefanie Schulz; Katharina Mayer; Isabell Bernlochner; Albert Schömig; Adnan Kastrati
Journal:  Eur Heart J       Date:  2011-04-28       Impact factor: 29.983

8.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

Authors:  Tamali Bhattacharyya; Stephen J Nicholls; Eric J Topol; Renliang Zhang; Xia Yang; David Schmitt; Xiaoming Fu; Mingyuan Shao; Danielle M Brennan; Stephen G Ellis; Marie-Luise Brennan; Hooman Allayee; Aldons J Lusis; Stanley L Hazen
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

9.  Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes.

Authors:  Tunay Senturk; Emre Sarandol; Sumeyye Gullulu; Selda Erdinc; Osman Ozdabakoglu; Bulent Ozdemir; Ibrahim Baran; Sinan Arslan; Ali Aydinlar
Journal:  Saudi Med J       Date:  2009-03       Impact factor: 1.484

10.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272
View more
  6 in total

Review 1.  Impact of genetic polymorphisms on platelet function and response to anti platelet drugs.

Authors:  Teresa Strisciuglio; Danilo Franco; Giuseppe Di Gioia; Chiara De Biase; Carmine Morisco; Bruno Trimarco; Emanuele Barbato
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 2.  Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Authors:  Adam S Fisch; Christina G Perry; Sarah H Stephens; Richard B Horenstein; Alan R Shuldiner
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 3.  A review of pharmacogenetics of adverse drug reactions in elderly people.

Authors:  Maurizio Cardelli; Francesca Marchegiani; Andrea Corsonello; Fabrizia Lattanzio; Mauro Provinciali
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

4.  Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.

Authors:  Yu Chen; Xiaohong Huang; Yong Tang; Yuquan Xie; Yachen Zhang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 5.  The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.

Authors:  Arwa M Amin; Lim Sheau Chin; Dzul Azri Mohamed Noor; Muhamad Ali Sk Abdul Kader; Yuen Kah Hay; Baharudin Ibrahim
Journal:  Cardiol Res Pract       Date:  2017-03-21       Impact factor: 1.866

Review 6.  Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Authors:  Christina G Perry; Alan R Shuldiner
Journal:  J Hum Genet       Date:  2013-05-23       Impact factor: 3.172
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.